A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an
aggressive but potentially curable malignancy. However, patients with early relapse (relapse
within 12 months since diagnosis or the end of first-line treatment, ER) or primary
refractory had an even worse prognosis. Thus, the investigators plan to evaluate the efficacy
and safety of anlotinib combined with rituximab, gemcitabine, oxaliplatin (A-RGEMOX) in the
treatment of early relapsed/refractory diffuse large B-cell lymphoma.